Discussion
The physiological role of Interleukin 6 (IL-6) has been advised to
participation in the pathogenesis of several diseases. These introduce
multiple myeloma, post-menopausal osteoporosis, and chronic autoimmune
diseases, where a stable association has been shown between disease
changes and increased production of the cytokine. For these reasons it
is commonly believed that potent IL-6 receptor antagonists will be
helpful therapeutic tools [4].
On the other hand, the renin-angiotensin system (RAS), a peptide based
system, has been classically recognized as a complex linear humoral
system. It gives to the control of cardiovascular, renal, and adrenal
functions [1]. The circulatory protease, renin is a key enzyme of
the RAS and is secreted. The RAS is one of the central members in
respiratory diseases such as acute respiratory distress syndrome (ARDS)
and acute lung injury (ALI) during sepsis [5]. ARDS is characterized
by pulmonary edema, severe hypoxia, and accumulation of inflammatory
cells [10]. One of the common indications of ARDS is a strong
inflammatory response, which is characterized by the release of
proinflammatory cytokines [5].
The effect of RAS is well known in the cardiovascular system in specific
in the control of blood pressure, vasoconstriction, cell growth and
cardiac remodelling. Inflammation and oxidative stress play an important
role with it [6].
Also, Rheumatoid arthritis (RA) is an inflammatory disease of joints. It
is related with increased risk of cardiovascular complications. The main
disadvantageous contributing factor for an increased mortality in RA is
the extent of associated systemic inflammation. Then it is opinion that
drugs was guessed can be effective and is suggested that pepstatin
inhibitor can be appropriate on interaction with SARS-CoV-2 for future
work.
Two models of chemical series selected from the above mentioned database
were modified these compounds by including substituents to have
interactions with SARS-CoV-2 spike protein receptor residues at S1
subunit.
The purpose of this article was to brief about antiSARS-CoV-2 spike
protein drugs (Pharmacokinetics and pharmacodynamics). Activated
inflammation, as demonstrated by persistently higher IL-6 levels, may
have profound and far-reaching clinical implications [16]. Even when
virologically contained, treated HIV-infected persons have significantly
higher plasma levels of IL-6 than well-matched uninfected controls
[17]. Changes in cytokine levels in HIV infected individuals can
affect the function of the immune system and have the potential to
directly impact the course of HIV disease effects of cytokines are
pleiotropic and are influenced by the concentrations, presence or
absence of other cytokines. Once produced, these factors may act
individually or together, directly or indirectly on infected cells,
activating cellular components of the intrinsic system and/or promoting
specific T- and B-cell adaptive responses to mediate anti-microbial
effects [18].
There are a number of pharmaceuticals before being tested, but a better
understanding of the underlying pathobiology is required. In this
context, this article was briefly reviewed the hypothesis for SARS-CoV-2
spike protein receptor as a specific target.
The same protocol applied to drugs forming complexes with ASN479.
Analysis of the number of hydrogen and hydrophobic bonds between drugs
and protein shows that the complex has a higher number of intermolecular
Van der Waals bonds, which indicates that it has higher affinity for
TYR442, TRP476, LEU478, LYS439 and ASP480 than others.
Theoretically, lostartan was the lowest energy obtained in docking
simulations, so that should be the best selection, but comparison
RefRMSs to expression standard deviation and the consideration inhibitor
constant, lamirudine can be the most effective and then favipiravir as
well as in the end, chloroquine, respectively. Hawever, anakinra is
proposed, because the only structure that interact with SARS-CoV-2 spike
protein by simulation vina software (Figure1-a).